相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
Thomas Bachelot et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report
Jeroen P. Jansen et al.
VALUE IN HEALTH (2014)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Denise A. Yardley et al.
ADVANCES IN THERAPY (2013)
Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making
Shannon Cope et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews
Joel J. Gagnier et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers
Jeroen P. Jansen et al.
BMC MEDICINE (2013)
Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis
Loukia M. Spineli et al.
CLINICAL TRIALS (2013)
The Impact of Using Informative Priors in a Bayesian Cost-Effectiveness Analysis: An Application of Endovascular versus Open Surgical Repair for Abdominal Aortic Aneurysms in High-Risk Patients
C. Elizabeth McCarron et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 7: A Reviewer's Checklist
A. E. Ades et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 3: HeterogeneitySubgroups, Meta-Regression, Bias, and Bias-Adjustment
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis
Felix A. Achana et al.
STATISTICS IN MEDICINE (2013)
Incorporating data from various trial designs into a mixed treatment comparison model
Susanne Schmitz et al.
STATISTICS IN MEDICINE (2013)
Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
Shannon Cope et al.
VALUE IN HEALTH (2013)
Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review
Aida Bafeta et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
Jeroen P. Jansen et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
William J. Gradishar et al.
CLINICAL BREAST CANCER (2012)
The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
Julia A. Beaver et al.
FUTURE ONCOLOGY (2012)
How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis
Edward J. Mills et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Assessing the consistency assumption by exploring treatment by covariate interactions in mixed treatment comparison meta-analysis: individual patient-level covariates versus aggregate trial-level covariates
Sarah Donegan et al.
STATISTICS IN MEDICINE (2012)
Mixed treatment comparisons using aggregate and individual participant level data
Pedro Saramago et al.
STATISTICS IN MEDICINE (2012)
Efficacy of Once-Daily Indacaterol Relative to Alternative Bronchodilators in COPD: A Patient-Level Mixed Treatment Comparison
Shannon Cope et al.
VALUE IN HEALTH (2012)
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
J. P. T. Higgins et al.
RESEARCH SYNTHESIS METHODS (2012)
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
Ian R. White et al.
RESEARCH SYNTHESIS METHODS (2012)
Network meta-analysis of survival data with fractional polynomials
Jeroen P. Jansen
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Bayesian Hierarchical Models Combining Different Study Types and Adjusting for Covariate Imbalances: A Simulation Study to Assess Model Performance
C. Elizabeth McCarron et al.
PLOS ONE (2011)
Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
David C. Hoaglin et al.
VALUE IN HEALTH (2011)
How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care Evaluation?
Nicola J. Cooper et al.
VALUE IN HEALTH (2011)
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
Jeroen P. Jansen et al.
VALUE IN HEALTH (2011)
Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical Oncology
Benoit Beuselinck et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
Checking consistency in mixed treatment comparison meta-analysis
S. Dias et al.
STATISTICS IN MEDICINE (2010)
Network meta-analysis of parametric survival curves
Mario J. N. M. Ouwens et al.
RESEARCH SYNTHESIS METHODS (2010)
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined
E. D. Saad et al.
ANNALS OF ONCOLOGY (2009)
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
N. Katsumata et al.
ANNALS OF ONCOLOGY (2009)
A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer
Denise A. Yardley et al.
CLINICAL BREAST CANCER (2009)
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
William J. Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bias modelling in evidence synthesis
Rebecca M. Turner et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY (2009)
Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation
Nicola J. Cooper et al.
STATISTICS IN MEDICINE (2009)
Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
Robert J. Paridaens et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment
Carl Richard Meier et al.
ONKOLOGIE (2008)
Evaluation of networks of randomized trials
Georgia Salanti et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2008)
Assessing evidence inconsistency in mixed treatment comparisons
Guobing Lu et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2006)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Combination of direct and indirect evidence in mixed treatment comparisons
G Lu et al.
STATISTICS IN MEDICINE (2004)
A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence
AE Ades
STATISTICS IN MEDICINE (2003)
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
R Paridaens et al.
ANNALS OF ONCOLOGY (2003)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)
GW Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Network meta-analysis for indirect treatment comparisons
T Lumley
STATISTICS IN MEDICINE (2002)
Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head
JA Berlin et al.
STATISTICS IN MEDICINE (2002)
Bayesian measures of model complexity and fit
DJ Spiegelhalter et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2002)
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
JA O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2001)
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over
R Paridaens et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
